Polaryx Therapeutics (PLYX) Common Equity (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Common Equity of $2.5 million for Q1 2026, down 41.51% year-over-year from $4.3 million in Q1 2025, and down 45.5% quarter-over-quarter from $4.6 million in Q4 2025.
Polaryx Therapeutics (PLYX) Common Equity (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Common Equity for 3 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 41.51% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 41.51% YoY), while the FY2025 annual figure was $4.6 million, down 3.12% from the prior year.
- Common Equity fell to $2.5 million in Q1 2026 per PLYX's latest filing, from $4.6 million in the prior quarter.
- Across five years, Common Equity topped out at $4.7 million in Q4 2024 and bottomed at $2.5 million in Q1 2026.
- Historically, Common Equity has averaged $4.0 million across 3 years, with a median of $4.4 million in 2025.
- Annual changes were most pronounced in 2025 — Common Equity declined 3.12% — and 2026, when it slumped 41.51%.
- Polaryx Therapeutics' Common Equity stood at $4.7 million in 2024, then declined by 3.12% to $4.6 million in 2025, then sank by 45.5% to $2.5 million in 2026.
- Business Quant data shows PLYX's Common Equity at $2.5 million in Q1 2026, $4.6 million in Q4 2025, and $4.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Polaryx Therapeutics | 102.35 Mn | 90.81 Mn | - | 10.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.94 Mn |
| Mar 31, 2026 | 2.49 Mn |
| Dec 31, 2025 | 4.57 Mn |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 4.71 Mn |